Literature DB >> 31665346

Esophageal melanoma: a systematic review and exploratory recurrence and survival analysis.

D Schizas1, K S Mylonas1, G Bagias2, A Mastoraki3, M Ioannidi3, P Kanavidis1, N Hasemaki1, I Karavokyros1, D Theodorou4, T Liakakos1.   

Abstract

Esophageal melanoma is a rare and poorly described malignancy. We sought to review all available data on the clinicopathological features, management options, and outcomes of patients with esophageal melanoma to guide clinicians working to treat these uncommon tumors. A systematic literature search of the PubMed, Embase, and Cochrane databases was performed. Exploratory recurrence and survival analyses were performed using previously-validated pooled Cox and logistic regression techniques for case reports and case series. Quality assessment of included studies was performed using the tools developed by the Joanna Briggs and the National Heart, Lung, and Blood Institutes. Fifty-nine studies were reviewed. A total of 93 patients with esophageal melanoma were identified. The mean patient age was 61.2 ± 10.6 years. Esophageal melanoma usually developed at the lower esophagus (48.4%). 90.3% of the patients were symptomatic at presentation, with dysphagia being the most common symptom (72%). Esophagectomy was performed in 91.4% of the patients. Postoperatively, 14 patients (15.1%) received adjuvant chemotherapy. Tumor recurrence was seen in 37 patients (39.8%). The median time to recurrence was 6 months. Disease-specific mortality was 43%. All-cause mortality was 46.1%. On multivariable Cox regression, older patient age (hazard ratio [HR] = 0.91, P = 0.008) and higher Melan-A expression (HR = 0.21; P = 0.029) were associated with a significantly lower risk of mortality. Higher S100 levels (HR = 37.4; P = 0.001) were predictive of poor survival. On logistic regression, large, ulcerated, lower esophageal tumors were significantly more likely to recur (P = 0.018, P = 0.013, and P = 0.027 respectively). Esophageal melanoma is a rare malignancy that tends to present with dysphagia. Most surgically-treated patients undergo esophagectomy. Large, ulcerated, lower esophageal lesions recur more frequently. Immunohistochemistry provides prognostic information regarding survival.
© The Author(s) 2019. Published by Oxford University Press on behalf of International Society for Diseases of the Esophagus. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  esophageal melanoma; esophagus; melanoma; recurrence; survival; systematic review

Year:  2019        PMID: 31665346     DOI: 10.1093/dote/doz083

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  3 in total

1.  Case Report: Primary melanoma of the gastroesophageal junction.

Authors:  Yasmine Hussein Agha; Nathaniel A Parker; Joel Alderson
Journal:  F1000Res       Date:  2020-06-02

2.  Primary malignant melanoma in gastroesophageal junction with 36 months' recurrence-free: a case report.

Authors:  Yili Dai; Yiyin Zhang; Yongle Chen; Xiaoxiao Fan; Hui Lin; Junhai Pan
Journal:  AME Case Rep       Date:  2022-07-25

3.  Clinicopathological characterization of ten patients with primary malignant melanoma of the esophagus and literature review.

Authors:  Sheng-Li Zhou; Lian-Qun Zhang; Xue-Ke Zhao; Yue Wu; Qiu-Yu Liu; Bo Li; Jian-Jun Wang; Rui-Jiao Zhao; Xi-Juan Wang; Yi Chen; Li-Dong Wang; Ling-Fei Kong
Journal:  World J Gastrointest Oncol       Date:  2022-09-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.